Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.

Autor: Wierda WG; The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: wwierda@mdanderson.org., Shah NN; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA., Cheah CY; Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, WA, Australia., Lewis D; Plymouth Hospitals NHS Trust, Derriford Hospital, Plymouth, UK., Hoffmann MS; The University of Kansas Cancer Center, Kansas City, KS, USA., Coombs CC; University of California Irvine Health, Chao Family Comprehensive Cancer Center, Orange, CA, USA., Lamanna N; Herbert Irving Comprehensive Cancer Center, New York-Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA., Ma S; Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Jagadeesh D; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA., Munir T; Department of Haematology, St James's University Hospital, Leeds, UK., Wang Y; Department of Hematology, Mayo Clinic, Rochester, MN, USA., Eyre TA; Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Centre, Oxford, UK., Rhodes JM; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., McKinney M; Duke Cancer Institute, Durham, NC, USA., Lech-Maranda E; Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Tam CS; Alfred Hospital and Monash University, Melbourne, Australia., Jurczak W; Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland., Izutsu K; National Cancer Center Hospital, Tokyo, Japan., Alencar AJ; Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA., Patel MR; Florida Cancer Specialists and Sarah Cannon Research Institute, Sarasota, FL, USA., Seymour JF; Alfred Hospital and Monash University, Melbourne, Australia., Woyach JA; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Thompson PA; Alfred Hospital and Monash University, Melbourne, Australia., Abada PB; Loxo Oncology, Indianapolis, IN, USA., Ho C; Loxo Oncology, Indianapolis, IN, USA., McNeely SC; Loxo Oncology, Indianapolis, IN, USA., Marella N; Loxo Oncology, Indianapolis, IN, USA., Nguyen B; Loxo Oncology, Indianapolis, IN, USA., Wang C; Eli Lilly, Indianapolis, IN, USA., Ruppert AS; Eli Lilly, Indianapolis, IN, USA., Nair B; Loxo Oncology, Indianapolis, IN, USA., Liu H; Loxo Oncology, Indianapolis, IN, USA., Tsai DE; Loxo Oncology, Indianapolis, IN, USA., Roeker LE; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ghia P; Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy.

Publikováno v: The Lancet. Haematology [Lancet Haematol] 2024 Sep; Vol. 11 (9), pp. e682-e692. Date of Electronic Publication: 2024 Jul 18.

Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.

Autor: Valle JW; Division of Cancer Sciences and Department of Medical Oncology, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK. Electronic address: juan.valle@manchester.ac.uk., Vogel A; Hannover Medical School, Hannover, Germany., Denlinger CS; Fox Chase Cancer Center, Philadelphia, PA, USA., He AR; Georgetown University Medical Center, Washington, DC, USA., Bai LY; China Medical University Hospital, China Medical University, Taichung, Taiwan., Orlova R; China Medical University Hospital, China Medical University, Taichung, Taiwan., Van Cutsem E; University Hospital Gasthuisberg and KU Leuven, Leuven, Belgium., Adeva J; University Hospital 12 de Octubre, Madrid, Spain., Chen LT; National Health Research Institutes, Miaoli, Taiwan., Obermannova R; Masaryk Memorial Cancer Institute, Brno, Czech Republic., Ettrich TJ; Ulm University Hospital, Ulm, Germany., Chen JS; Linkou Chang Gung Memorial Hospital and Chang Gung University, Tao-Yuan, Taiwan., Wasan H; Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK., Girvan AC; Eli Lilly and Company, Indianapolis, IN, USA., Zhang W; Eli Lilly and Company, Indianapolis, IN, USA., Liu J; Eli Lilly and Company, Indianapolis, IN, USA., Tang C; Eli Lilly and Company, Indianapolis, IN, USA., Ebert PJ; Eli Lilly and Company, Indianapolis, IN, USA., Aggarwal A; Eli Lilly and Company, Indianapolis, IN, USA., McNeely SC; Eli Lilly and Company, Indianapolis, IN, USA., Moser BA; Eli Lilly and Company, Indianapolis, IN, USA., Oliveira JM; Eli Lilly and Company, New York, NY, USA., Carlesi R; Eli Lilly and Company, Sesto Fiorentino, Florence, Italy., Walgren RA; Eli Lilly and Company, Indianapolis, IN, USA., Oh DY; Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2021 Oct; Vol. 22 (10), pp. 1468-1482.

A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib.

Autor: Blosser WD; Eli Lilly and Company, Indianapolis, IN, USA., Dempsey JA; Eli Lilly and Company, Indianapolis, IN, USA., McNulty AM; Eli Lilly and Company, Indianapolis, IN, USA., Rao X; Eli Lilly and Company, Indianapolis, IN, USA., Ebert PJ; Eli Lilly and Company, Indianapolis, IN, USA., Lowery CD; Eli Lilly and Company, Indianapolis, IN, USA., Iversen PW; Eli Lilly and Company, Indianapolis, IN, USA., Webster YW; Eli Lilly and Company, Indianapolis, IN, USA., Donoho GP; Eli Lilly and Company, Indianapolis, IN, USA., Gong X; Eli Lilly and Company, Indianapolis, IN, USA., Merzoug FF; Eli Lilly and Company, Indianapolis, IN, USA., Buchanan S; Eli Lilly and Company, Indianapolis, IN, USA., Boehnke K; Eli Lilly and Company, New York, NY, USA., Yu C; Eli Lilly and Company, Shanghai, China., You XT; Eli Lilly and Company, Shanghai, China., Beckmann RP; Eli Lilly and Company, Indianapolis, IN, USA., Wu W; Eli Lilly and Company, Indianapolis, IN, USA., McNeely SC; Eli Lilly and Company, Indianapolis, IN, USA., Lin AB; Eli Lilly and Company, Indianapolis, IN, USA., Martinez R; Eli Lilly and Company, Indianapolis, IN, USA.

Publikováno v: Oncotarget [Oncotarget] 2020 Jan 21; Vol. 11 (3), pp. 216-236. Date of Electronic Publication: 2020 Jan 21 (Print Publication: 2020).

The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.

Autor: Landau HJ; Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Landauh@mskcc.org, McNeely SC, Nair JS, Comenzo RL, Asai T, Friedman H, Jhanwar SC, Nimer SD, Schwartz GK

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2012 Aug; Vol. 11 (8), pp. 1781-8. Date of Electronic Publication: 2012 May 31.